Paris

• TAR-0520 gel in EGFR inhibitor-induced folliculitis Recruiting
  2024-516339-28-00 4 2025-02-10 EGFR inhibitor-induced folliculitis
• KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer Recruiting
  2022-501854-12-01 1 2025-02-05 G12D/G12V Pancreatic Ductal Adenocarcinoma
• Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding … Recruiting
  2024-518368-10-00 7 2025-01-29 Recessive dystrophic epidermolysis bullosa (RDEB)
• HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA … Recruiting
  2024-519132-17-00 4 2025-01-29 NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA
• LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of … Recruiting
  2024-513356-15-00 5 2024-12-30 Acquired Blepharoptosis
• A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma Recruiting
  2024-513077-48-00 5 2024-12-19 O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
• Impact of Inhaled BGF 160 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient Recruiting
  2024-514097-52-00 6 2024-12-16 Impact of inhaled BGF 160 on complexity and variability of tidal breat
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor
• Fecal transplantation to Eradicate Colonizing Emergent Superbugs Recruiting
  2024-516393-29-00 5 2024-12-03 Patients colonized with MDR-GNB
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting
  2024-514135-17-00 5 2024-11-28 Immunoglobulin A Nephropathy
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla … Recruiting
  2023-507746-83-00 5 2024-11-27 Generalized Myasthenia Gravis
• NEOADJUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MU … Recruiting
  2024-519113-59-00 4 2024-11-20 Hepatocellular carcinoma
• Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial Recruiting
  2024-514799-42-00 4 2024-11-05 IDIOPATHIC PULMONARY FIBROSIS
• Lessening Organ Dysfunction with VITamin C in septic ARDS Recruiting
  2024-516394-78-00 5 2024-11-05 Patient with sepsis complicated by ARDS
• Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed b … Recruiting
  2024-518143-38-00 10 2024-10-25 Metastatic pancreatic cancer
• The ENERGY 2 Study: A study to investigate if study drug INZ-701 increases survival in infants with ENPP1 Deficiency by preventing heart dys … Recruiting
  2024-512991-36-00 5 2024-10-24 Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
• CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al … Recruiting
  2024-517004-11-00 5 2024-10-22 Chronic pulmonary aspergillosis
• Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting
  2024-513219-29-00 5 2024-10-21 Renal Cell Carcinoma
• A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c … Recruiting
  2023-505606-42-00 5 2024-10-15 Head and Neck Squamous Cell Carcinoma (HNSCC)
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 Melanoma
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Recruiting
  2023-510022-33-00 5 2024-10-03 HIV-1 infection
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 4 2024-10-02 Locally advanced or metastatic urothelial cancer

Showing 361–384 of 2,322 trials